AtheroGenics Cuts 50% of Jobs to Focus on Heart Drug
May 25 (Reuters) - Drug company AtheroGenics Inc. cut about 50 percent of its workforce in what it said was a first step in new plans for its failed heart drug AGI-1067, it said in a regulatory filing.